A gold-standard cancer treatment is in decline, and money may be why

December 12, 2017, University of Virginia

The evidence is clear: Cervical cancer is best treated with brachytherapy, a form of radiation therapy. Yet the use of this potentially lifesaving treatment has been declining, and a new study from the University of Virginia School of Medicine may explain why.

UVA researchers have determined that offering for locally advanced ends up costing hospitals money. After accounting for the costs and time involved, the researchers found that Medicare reimburses four times more per minute required for a less effective alternative than it does for brachytherapy. Ultimately, providing brachytherapy results in a net loss for the providing healthcare facility, the researchers determined. This can leave hospitals - particularly smaller hospitals that don't do a lot of brachytherapy - in the lurch.

"Studies have time and time again shown that brachytherapy is the most important part of cervical cancer treatment, because it is essential to eradicating the tumor," said Timothy Showalter, MD, a oncologist at UVA Cancer Center. "A decline in brachytherapy utilization is associated with a higher rate of mortality in cervical cancer, so there's a direct relationship."

Efficiency Vs. Effectiveness

The problem stems partly from the amount of physician time brachytherapy requires: It takes 80+ percent more personnel time to administer brachytherapy than it does to deliver the increasingly popular alternative, external beam radiation. Both methods deliver radiation to the tumor, but brachytherapy delivers much greater doses in a much more targeted manner. Another key difference, the researchers found: Medicare reimbursement makes external beam radiation profitable, while brachytherapy is not.

Overall, the researchers determined that it costs hospitals more than twice as much to provide brachytherapy as it does to provide external-beam radiation. But the reimbursement doesn't reflect that.

"Brachytherapy requires a lot of physician effort and expertise and reimburses poorly for that effort," Showalter said. "I can certainly imagine how the comparatively poor reimbursement rates compared to could contribute in some environments to not establishing a service for brachytherapy or just not committing physician time to it."

He noted that healthcare providers face a cold, hard truth when deciding whether to offer brachytherapy, or any other treatment: "If practices don't run at least a profit greater than zero," he said, "then they fold."

Best Places for Brachytherapy

The researchers concluded that hospitals that see a high volume of patients, such as UVA, are best equipped to provide brachytherapy - and to absorb the major resource commitment that comes with it. "My job specifically involves brachytherapy," Showalter said. "We're at this big with all the equipment we need at the ready and a wonderful streamlined process that enhances the patient experience and reduces patients' time on the table. That makes it easier to provide efficient and effective care."

"At UVA, we are particularly proud of our brachytherapy program and delivering quality brachytherapy is a top priority for us," he said. "We are fortunate that these financial considerations have not impacted our center, but these pressures could be a real barrier for smaller centers."

He expressed grave concern about the declining use of brachytherapy: "It's disturbing because we have this great treatment option that's an absolute requirement of curative therapy, and it's been available for decades, but the rates of actually using it are dropping," Showalter said. "It's like if you had an effective drug and people stopped using it."

Explore further: International trial confirms safety, effectiveness of HDR brachytherapy for cervical cancer

More information: Kristine Bauer-Nilsen et al, Evaluation of Delivery Costs for External Beam Radiation Therapy and Brachytherapy for Locally Advanced Cervical Cancer Using Time-Driven Activity-Based Costing, International Journal of Radiation Oncology*Biology*Physics (2017). DOI: 10.1016/j.ijrobp.2017.09.004

Related Stories

International trial confirms safety, effectiveness of HDR brachytherapy for cervical cancer

September 25, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly ...

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer

March 28, 2017
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer. The update provides ...

Brachytherapy reduced death rates in high-risk prostate cancer patients, study finds

January 25, 2012
Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise. A population-based ...

Less than half of cervical cancer patients receive standard-of-care treatment

October 31, 2016
Standard-of-care treatment for locally advanced cervical cancer includes radiation, chemotherapy and brachytherapy (in which radiation is implanted internally). A University of Colorado Cancer Center study published in the ...

Brachytherapy to treat cervical cancer declines in US, treatment associated with higher survival

September 11, 2013
A study by researchers at Brigham and Women's Hospital (BWH) found that brachytherapy treatment was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis ...

Brachytherapy improves survival for inoperable early stage endometrial cancer

April 25, 2015
Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ...

Recommended for you

Breath test breakthrough for early diagnosis of oesophageal and gastric cancer

May 18, 2018
A breath test can successfully detect oesophageal and gastric cancer and could be used as a first-line test for patients, say researchers.

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

Particle shows promise to prevent the spread of triple-negative breast cancer

May 18, 2018
USC researchers have pinpointed a remedy to prevent the spread of triple-negative breast cancer. Metastatic breast cancer is a leading cause of death for women. The findings appear today in Nature Communications.

Dilemma for cancer patients as life-saving meds are tied to vision loss

May 18, 2018
(HealthDay)—A newer type of cancer treatment may offer the chance of longer survival, but the drugs could also trigger new side effects, such as vision problems.

Polygenic scores to classify cancer risk

May 18, 2018
Polygenic risk scores could be useful to stratify the risk of several cancers among patients in medical centers, allowing for the potential discovery of new associations between genes, disease and secondary effects, according ...

A way to prevent pancreatic cancer from spreading post-surgery?

May 17, 2018
Scientists at Cold Spring Harbor Laboratory (CSHL) have solved a mystery about how pancreatic cancer spreads following surgery in patients whose tumor is successfully removed. After surgery, patients' typically experience ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.